Search Results

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.

• Authors : SPORTIF (Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation) III Investigators. Executive Steering Committee (CORPORATE AUTHOR); Olsson, S Bertil (AUTHOR); Executive Steering Committee of the SPORTIF III Investigators (CORPORATE AUTHOR)

• Source: Lancet. 11/22/2003, Vol. 362 Issue 9397, p1691-1698. 8p.

Record details

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.

• Authors : Wallentin L (AUTHOR); Wilcox RG (AUTHOR); Weaver WD (AUTHOR)

• Source: Lancet. 9/6/2003, Vol. 362 Issue 9386, p789-797. 9p.

Record details

Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.

• Authors : Direct Thrombin Inhibitor Trialists' Collaborative Group (CORPORATE AUTHOR)

• Source: Lancet. 1/26/2002, Vol. 359 Issue 9303, p294-302. 9p.

Record details

Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

• Authors : Schulman S (AUTHOR); Wåhlander K (AUTHOR); Lundström T (AUTHOR)

• Source: New England Journal of Medicine. 10/30/2003, Vol. 349 Issue 18, p1713-1721. 9p.

Record details

Prospective, Randomized, Phase II, Non-Inferiority Study to Evaluate the Safety and Efficacy of Topical Thrombin (Human) Grifols as Adjunct to Hemostasis During Vascular, Hepatic, Soft Tissue, and Spinal Open Surgery.

• Authors : Minkowitz, Harold¹ (AUTHOR) ; Navarro-Puerto, Jordi² (AUTHOR); Lakshman, Shankar³ (AUTHOR)

Subjects: *THROMBIN; *SPINAL surgery; *HEMOSTASIS

• Source: Journal of the American College of Surgeons. Nov2019, Vol. 229 Issue 5, p497-497. 1p.

Record details

Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study.

• Authors : Petersen P (AUTHOR); Grind M (AUTHOR); Adler J (AUTHOR)

• Source: Journal of the American College of Cardiology (JACC). May2003, Vol. 41 Issue 9, p1445-1451. 7p.

Record details

Annexin A5 haplotypes in the antiphospholipid syndrome.

• Authors : Hiddink L; Department of Laboratory Medicine, Laboratory of Hematology, Radboudumc, Nijmegen, the Netherlands.; de Laat B

Subjects: Annexin A5/Annexin A5/Annexin A5/*genetics ; Antibodies, Antiphospholipid/Antibodies, Antiphospholipid/Antibodies, Antiphospholipid/*genetics ; Antiphospholipid Syndrome/Antiphospholipid Syndrome/Antiphospholipid Syndrome/*genetics

• Source: Thrombosis research [Thromb Res] 2015 Feb; Vol. 135 (2), pp. 417-9. Date of Electronic Publication: 2014 Dec 05.Publisher: Pergamon Press Country of Publication: United States NLM ID: 0326377 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Antibodies against domain I of β2-glycoprotein I: the one and only?

• Authors : Pelkmans L; Laboratory of the Pathophysiology of Thrombin Generation, Department of Biochemistry, CARIM, Maastricht University Medical Centre, The Netherlands.; de Laat B

Subjects: Antiphospholipid Syndrome/Antiphospholipid Syndrome/Antiphospholipid Syndrome/*immunology ; Autoantibodies/Autoantibodies/Autoantibodies/*immunology ; beta 2-Glycoprotein I/beta 2-Glycoprotein I/beta 2-Glycoprotein I/*immunology

• Source: Lupus [Lupus] 2012 Jun; Vol. 21 (7), pp. 769-72.Publisher: SAGE Publications Country of Publication: England NLM ID: 9204265 Publication Model: Print Cited Medium: Internet ISSN: 1477-0962

Record details